News
Evolus Announces Publication Of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau
17 Apr 24
Biotech, News, General
Needham Reiterates Buy on Evolus, Maintains $22 Price Target
10 Apr 24
News, Price Target, Reiteration, Analyst Ratings
12 Health Care Stocks Moving In Thursday's After-Market Session
21 Mar 24
Movers
Evolus Reports Pricing Of $50M Offering Of Common Stock
11 Mar 24
News, Offerings
Stifel Reiterates Buy on Evolus, Raises Price Target to $25
8 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Needham Reiterates Buy on Evolus, Maintains $22 Price Target
8 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Mizuho Maintains Buy on Evolus, Raises Price Target to $23
8 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $27 Price Target
8 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Recap: Evolus Q4 Earnings
7 Mar 24
Earnings
Evolus Q4 2023 GAAP EPS $(0.210) Misses $(0.200) Estimate, Sales $60.999M Beat $60.056M Estimate
7 Mar 24
Earnings, Earnings Beats, Earnings Misses, News
Earnings Scheduled For March 7, 2024
7 Mar 24
Earnings
Earnings Outlook For Evolus
6 Mar 24
Earnings
HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $27 Price Target
1 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Evolus Announces Results From European Head-To-Head Filler Trial; European Lift Study Met The Primary Endpoint Of Non-Inferiority
1 Mar 24
Biotech, News, General
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
29 Jan 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Barclays Upgrades Evolus to Overweight, Raises Price Target to $16
29 Jan 24
News, Upgrades, Price Target, Analyst Ratings
Press releases
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®
17 Apr 24
Press Releases
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Apr 24
Press Releases
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
11 Mar 24
Press Releases
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 Mar 24
Press Releases
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
7 Mar 24
Press Releases
Evolus Announces Results from European Head-to-Head Filler Trial
1 Mar 24
Press Releases
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
22 Feb 24
Press Releases
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9 Feb 24
Press Releases